Norsolorinic acid inhibits proliferation of T24 human bladder cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a FAS/membrane-bound FAS ligand-mediated apoptotic pathway

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 11, 2008, Pages 1301-1308

  Wang, Clay C C ^a   Chiang, Yi Ming ^a,b   Kuo, Po Lin ^b   Chang, Jiunn Kae ^b   Hsu, Ya Ling ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Apoptosis; Bladder cancer; Cell cycle; Fas; Norsolorinic acid

Indexed keywords

ACID; CASPASE 8; CYTOKINE RECEPTOR; FAS ANTIGEN; FAS LIGAND; FAS RECEPTOR; NORSOLORINIC ACID; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASPERGILLUS NIDULANS; BLADDER CANCER; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANTHRAQUINONES; ANTIGENS, CD95; APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; FAS LIGAND PROTEIN; G0 PHASE; G1 PHASE; GROWTH INHIBITORS; HUMANS; MEMBRANE PROTEINS; PROTEIN BINDING; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 54249162366     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05007.x     Document Type: Article

References (37)

1. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 1997 58 : 62 7.
2. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J. Urol. 1997 15 : 84 8.
3. Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther. 2005 12 : 12 18.
4. Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002 2 : 277 88.
5. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol. Cancer Ther. 2003 2 : 573 80.
6. Lin JG, Chen GW, Li TM, Chouh ST, Tan TW, Chung JG. Aloe-emodin induces apoptosis in T24 human bladder cancer cells through the p53 dependent apoptotic pathway. J. Urol. 2006 175 : 343 7.
7. Perabo FG, Wirger A, Kamp S et al. Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2. Anticancer Res. 2004 24 : 2869 77.
8. Mizutani Y, Yoshida O, Bonavida B. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). J. Urol. 1998 160 : 561 70.
9. Nagata S, Golstein P. The Fas death factor. Science 1995 267 : 1449 56.
10. Juo P, Kuo CJ, Yuan L, Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol. 1998 8 : 1001 8.
11. Yamazaki M, Satoh Y, Maebayashi Y, Horie Y. Monoamine oxidase inhibitors from a fungus, Emericella navahoensis. Chem. Pharm. Bull. 1988 36 : 670 5.
12. Cove DJ. The induction and repression of nitrate reductase in the fungus Aspergillus nidulans. Biochim. Biophys. Acta 1966 113 : 51 6.
13. Xu Z, Choudhary S, Voznesensky O et al. Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis. Cancer Res. 2006 66 : 6657 64.
14. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol. Cancer Ther. 2004 3 : 11 20.
15. Kuo YC, Kuo PL, Hsu YL, Cho CY, Lin CC. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 2006 78 : 2550 7.
16. Kuo PL, Hsu YL, Lin TL, Lin CC. The antiproliferative activity of prodelphinidin B-2,3′-O-gallate from green tea leaf is through cell cycle arrest and Fas-mediated apoptotic pathway in A549 cells. Food Chem. Toxicol. 2005 43 : 315 23.
17. Hsu YL, Kuo PL, Lin LT, Lin CC. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J. Pharmacol. Exp. Ther. 2005 313 : 333 44.
18. Freedman VH, Shin SI. Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium. Cell 1974 3 : 355 9.
19. Shin SI, Freedman VH, Risser R, Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc. Natl Acad. Sci. USA 1975 72 : 4435 9.
20. May P, May E. Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene 1999 18 : 7621 36.
21. Lee SH, Lee JY, Park WS, Kim SY, Jang JJ, Yoo NJ. Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU Int. 1999 83 : 698 702.
22. Perabo FG, Mattes RH, Wirger A et al. Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo. Urol. Oncol. 2001 6 : 163 9.
23. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993 366 : 707 10.
24. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993 75 : 805 16.
25. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993 366 : 701 4.
26. Dulic V, Kaufmann WK, Wilson SJ et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994 76 : 1013 23.
27. el-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993 75 : 817 25.
28. Macleod KF, Sherry N, Hannon G et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995 9 : 935 44.
29. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994 54 : 3391 5.
30. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr. Opin. Cell Biol. 2003 15 : 164 71.
31. Hengartner MO. The biochemistry of apoptosis. Nature 2000 407 : 770 6.
32. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993 75 : 1169 78.
33. Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 1995 182 : 1777 83.
34. Mizutani Y, Yoshida O. Effect of anticancer agents on Fas-mediated cytotoxicity against bladder cancer cells. J. Infect. Chemother. 1999 5 : 139 43.
35. Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer 1997 79 : 1180 9.
36. Yang CH, Craise LM. Development of human epithelial cell systems for radiation risk assessment. Adv. Space Res. 1994 14 : 115 20.
37. Jefford CE, Irminger-Finger I. Mechanisms of chromosome instability in cancers. Crit. Rev. Oncol. Hematol. 2006 59 : 1 14.